OncoMatch/Clinical Trials/NCT06060613
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Is NCT06060613 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies OBX-115 for tumor skin.
Treatment: OBX-115 — This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Melanoma
Non-Small Cell Lung Carcinoma
Biomarker criteria
Excluded: GNA11 any
melanoma of uveal origin or its other genetic equivalents (e.g. GNA11 and GNAQ)
Excluded: GNAQ any
melanoma of uveal origin or its other genetic equivalents (e.g. GNA11 and GNAQ)
Disease stage
Required: Stage IV
Metastatic disease required
advanced/metastatic melanoma or relapsed refractory metastatic non-small cell lung cancer (NSCLC)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-PD-1 therapy — systemic therapy for unresectable or metastatic melanoma
must have experienced documented radiographic disease progression after systemic therapy containing a programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) blocking antibody
Cannot have received: second line cytotoxic chemotherapy
Exception: if already received cytotoxic chemotherapy in the first line setting
must not have been exposed to any second line cytotoxic chemotherapy if they have already received cytotoxic chemotherapy in the first line setting
Lab requirements
Blood counts
protocol specified hematologic parameters for absolute neutrophil count (anc) and platelet count
Kidney function
adequate kidney function as specified in the protocol
Liver function
adequate liver function as specified in the protocol
Cardiac function
adequate cardiac function as specified in the protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M.D. Anderson Cancer Center (Melanoma/NSCLC) · Houston, Texas
- The Angeles Clinic and Research Institute (Melanoma) · Los Angeles, California
- USC Norris Comprehensive Cancer Center (Melanoma/NSCLC) · Los Angeles, California
- Stanford Cancer Institute (Melanoma/NSCLC) · Stanford, California
- Orlando Health Cancer Institute (Melanoma/NSCLC) · Orlando, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06060613 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior second line cytotoxic chemotherapy disqualifies patients from enrollment.
Are patients with GNA11 alterations eligible?
No. GNA11 any is an exclusion criterion.
Are patients with GNAQ alterations eligible?
No. GNAQ any is an exclusion criterion.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages